Renal Cell Cancer, Recurrent Completed Phase 1 Trials for Trastuzumab (DB00072)

Also known as: Recurrent Renal Cell Cancer

IndicationStatusPhase
DBCOND0082537 (Renal Cell Cancer, Recurrent)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00004074Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuTreatment